Cytosorbents Future Growth
Future criteria checks 2/6
Cytosorbents is forecast to grow earnings and revenue by 53.8% and 22.3% per annum respectively while EPS is expected to grow by 55.4% per annum.
Key information
53.8%
Earnings growth rate
55.4%
EPS growth rate
| Medical Equipment earnings growth | 14.2% |
| Revenue growth rate | 22.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 53 | -6 | -12 | -11 | 3 |
| 12/31/2025 | 43 | -13 | -21 | -20 | 3 |
| 12/31/2024 | 39 | -17 | -26 | -26 | 3 |
| 9/30/2024 | 38 | -19 | -19 | -18 | N/A |
| 6/30/2024 | 37 | -26 | -22 | -21 | N/A |
| 3/31/2024 | 37 | -28 | -24 | -23 | N/A |
| 12/31/2023 | 36 | -29 | -23 | -22 | N/A |
| 9/30/2023 | 37 | -23 | -22 | -21 | N/A |
| 6/30/2023 | 36 | -26 | -24 | -22 | N/A |
| 3/31/2023 | 35 | -31 | -30 | -23 | N/A |
| 12/31/2022 | 35 | -33 | -35 | -28 | N/A |
| 9/30/2022 | 36 | -41 | -36 | -28 | N/A |
| 6/30/2022 | 38 | -36 | -34 | -26 | N/A |
| 3/31/2022 | 41 | -29 | -24 | -20 | N/A |
| 12/31/2021 | 43 | -25 | -18 | -14 | N/A |
| 9/30/2021 | 44 | -16 | -12 | -10 | N/A |
| 6/30/2021 | 45 | -10 | -11 | -9 | N/A |
| 3/31/2021 | 43 | -9 | -7 | -5 | N/A |
| 12/31/2020 | 41 | -8 | -7 | -6 | N/A |
| 9/30/2020 | 36 | -11 | -10 | -9 | N/A |
| 6/30/2020 | 32 | -17 | -12 | -11 | N/A |
| 3/31/2020 | 28 | -18 | -17 | -16 | N/A |
| 12/31/2019 | 25 | -19 | -18 | -17 | N/A |
| 9/30/2019 | 24 | -21 | -17 | -15 | N/A |
| 6/30/2019 | 23 | -17 | -14 | -13 | N/A |
| 3/31/2019 | 23 | -19 | -14 | -13 | N/A |
| 12/31/2018 | 23 | -17 | -12 | -11 | N/A |
| 9/30/2018 | 21 | -15 | -10 | -9 | N/A |
| 6/30/2018 | 19 | -14 | N/A | -8 | N/A |
| 3/31/2018 | 17 | -10 | N/A | -7 | N/A |
| 12/31/2017 | 15 | -9 | N/A | -6 | N/A |
| 9/30/2017 | 14 | -11 | N/A | -7 | N/A |
| 6/30/2017 | 12 | -10 | N/A | -7 | N/A |
| 3/31/2017 | 11 | -11 | N/A | -7 | N/A |
| 12/31/2016 | 10 | -12 | N/A | -7 | N/A |
| 9/30/2016 | 8 | -9 | N/A | -8 | N/A |
| 6/30/2016 | 7 | -10 | N/A | -8 | N/A |
| 3/31/2016 | 6 | -5 | N/A | -8 | N/A |
| 12/31/2015 | 5 | -9 | N/A | -9 | N/A |
| 9/30/2015 | 4 | -17 | N/A | -9 | N/A |
| 6/30/2015 | 4 | -17 | N/A | -9 | N/A |
| 3/31/2015 | 4 | -21 | N/A | -8 | N/A |
| 12/31/2014 | 4 | -19 | N/A | -6 | N/A |
| 9/30/2014 | 4 | -9 | N/A | -5 | N/A |
| 6/30/2014 | 4 | -8 | N/A | -4 | N/A |
| 3/31/2014 | 3 | -7 | N/A | -3 | N/A |
| 12/31/2013 | 2 | -7 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HQE1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HQE1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HQE1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HQE1's revenue (22.3% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: HQE1's revenue (22.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HQE1's Return on Equity is forecast to be high in 3 years time